nx_supp_channel.nx

nx_supp_channel.nx -- SUPPLEMENT GTM SUITE / COMMERCIAL CHANNEL rung. "Which regulator is most permissive" is the wrong question, and this file exists to replace it with the right one: WHICH CHANNEL is this substance lawful in, and what does that channel demand. A substance is not simply legal or illegal. It is legal THROUGH a route: retail supplement -- DSHEA, no prescriber, no premarket approval (ODI) OTC drug -- an existing monograph, no prescriber compounded Rx -- 503A pharmacy, patient-specific prescription outsourcing facility-- 503B, office stock, cGMP, FDA-registered approved drug -- NDA / ANDA / BLA Ask "where is it permitted" and the answer is a country. Ask "through what route" and the answer is a business model. THE ANSWER THAT SURPRISES PEOPLE. For the peptide category the United States is among the MOST permissive jurisdictions on earth -- not through the supplement shelf, which is firmly closed to peptides, but through SECTION 503A COMPOUNDING. A licensed prescriber plus a compounding pharmacy is a real, legal, and large channel, and it is exactly how compounded oxytocin troches and the whole "peptide clinic" model operate. Most countries have nothing comparable. So the instinct to look abroad for permissiveness usually ends up pointing back home, at a channel that was available the whole time and simply requires a prescriber. BUT 503A IS NOT A LOOPHOLE, AND THIS FILE ENCODES WHY. A bulk drug substance may only be compounded under 503A if it satisfies at least ONE of three prongs (FD&C Act 503A(b)(1)(A)(i)): 1. it is the subject of an approved application, OR 2. it appears in a USP or NF monograph, OR 3. it appears on FDA's 503A bulk drug substances list. Oxytocin passes prong 1 -- it is an approved drug substance -- so a patient-specific compounded preparation is lawful. Kisspeptin-10 passes NONE of the three. BPC-157 was placed in 503A CATEGORY 2 in 2023, explicitly not eligible. So the same channel that legitimises one peptide forecloses another, by a rule, on the record -- which is the difference between a regulated channel and an unpoliced one. WHAT NO CHANNEL AND NO COUNTRY WILL DO. Manufacturing offshore does not create a route to a US consumer: FDA jurisdiction attaches at import and to marketing directed at US buyers, so "make it in X, ship to US customers" is